4978.T
ReproCELL Incorporated
グロース · 化学 · 素材・化学 · JP
JPY 116.00
−2.52%Oct 20, 2026, 22:32 UTC
Japanese shares listed in the item moved on October 20, with the named stocks recording the reported closing prices and daily changes.
Source:Oct 20, 2026, 00:49 UTC
ReproCELL announced that it had finalized the clinical trial protocol for its GPC-1 CAR-T therapy for recurrent esophageal squamous cell carcinoma after completing consultations with Japan's Pharmaceuticals and Medical Devices Agency.
Source:Oct 5, 2026, 20:50 UTC
ReproCELL conducted a third-party allotment of 2,932,000 new shares to CVI Investments at an issue price of 119 yen.
Source:Sep 30, 2026, 22:32 UTC
ReproCELL and Toho Holdings reached a basic agreement on domestic distribution of the regenerative medicine product 'StemKaimaru'.
Source:Sep 30, 2026, 00:17 UTC
ReproCELL developed the supplement Gutama Aging, positioned as part of a new Well-Aging business, to be rolled out in its BtoC operations.
Source:Sep 29, 2026, 11:00 UTC
ReproCELL signed a basic agreement with Toho Holdings for a partnership on domestic distribution of the regenerative medicine product 'Stemchymal', which is under marketing approval application.
Sep 28, 2026, 11:00 UTC
ReproCELL signed a collaboration agreement with US AI-driven biotechnology company Polyphron to advance AI-driven human tissue research using iPS cells.
Sep 24, 2026, 04:07 UTC
ReproCELL obtained a regenerative medicine product manufacturing and marketing license from Kanagawa Prefecture, dated the 18th, advancing its readiness to supply StemKaiMaru in Japan once approved.
Source:Sep 17, 2026, 11:00 UTC
ReproCELL received a subsidy grant decision notice under AMED's public program for base technology development toward industrialization of regenerative medicine and gene therapy.
Source:Aug 19, 2026, 20:50 UTC
Reprocell announced a third-party allotment of 2,932,000 new shares to CVI Investments at an issue price of 140 yen per share.
Source: